Confirm hereditary ATTR rather than assuming every amyloidosis is the same disease
ATTRv must be distinguished from wild-type ATTR and from acquired amyloidoses such as AL amyloidosis because genetics, treatment and family implications differ. A pathogenic TTR variant supports hereditary disease, but clinicians should still confirm that the clinical phenotype and any tissue amyloid typing are consistent with ATTR rather than attributing every neuropathy or cardiomyopathy to an incidental variant.
TTR genetic testing defines the hereditary diagnosis and family pathway
More than one amyloidogenic TTR variant can produce neuropathic, cardiac or mixed phenotypes. Molecular confirmation should include expert variant interpretation and genetic counseling because the condition is autosomal dominant and penetrance and age at onset vary. Once a familial pathogenic variant is established, predictive testing of asymptomatic relatives should occur through an appropriate counseling pathway rather than as unsupervised direct-to-consumer testing.
Neuropathy staging should document more than numb feet
Specialist assessment can include neurological examination, nerve-conduction studies/EMG and standardized disability measures, together with autonomic symptoms such as orthostatic intolerance, gastrointestinal dysmotility, erectile dysfunction and bladder problems. Heidelberg's Neurology Amyloidosis Clinic has a long-standing focus on familial amyloid polyneuropathy and integrates neurological amyloidosis care with MR neurography and cardiology.
Cardiac assessment matters even when neuropathy is the presenting problem
ATTRv can be predominantly neuropathic, predominantly cardiac or mixed. ECG, echocardiography, cardiac biomarkers, cardiac MRI and bone-tracer scintigraphy may be used according to the clinical question. A treatment decision for hATTR polyneuropathy should therefore not ignore cardiomyopathy, rhythm disease, heart-failure symptoms or the possibility that the cardiac component influences overall therapy selection.
Patisiran is an EU-authorised siRNA option for stage 1 or 2 hATTR polyneuropathy
EMA authorises Onpattro (patisiran) for adults with hereditary transthyretin-mediated amyloidosis and stage 1 or stage 2 polyneuropathy. It is administered by intravenous infusion and requires specialist supervision, infusion-reaction precautions and vitamin A supplementation. Its logistics differ substantially from subcutaneous silencers and should be considered alongside the patient's travel and long-term treatment plan.
Vutrisiran is a subcutaneous TTR-silencing option with both neuropathy and cardiomyopathy indications
EMA authorises Amvuttra (vutrisiran) for adults with hereditary ATTR and stage 1 or 2 polyneuropathy. Its EU indication has also expanded to ATTR cardiomyopathy in adults, including hereditary and non-hereditary ATTR. In a mixed neurological-cardiac phenotype, that broader label can be clinically relevant, but it does not remove the need for separate neurological and cardiology staging.
Eplontersen added another authorised stage 1 or 2 polyneuropathy pathway in 2025
Wainzua (eplontersen) received EU marketing authorisation in March 2025 for adults with ATTRv and stage 1 or 2 polyneuropathy. It is an antisense oligonucleotide given as a monthly subcutaneous injection, and vitamin A supplementation is part of treatment. A German center can compare it with other silencers using disease stage, prior therapy, adverse-effect profile, administration route and follow-up practicalities.
Tafamidis remains authorised for stage-1 symptomatic transthyretin polyneuropathy
EMA's current Vyndaqel information continues to include adult stage-1 symptomatic polyneuropathy to delay peripheral neurological impairment. Tafamidis stabilizes the TTR tetramer rather than suppressing TTR production. The presence of newer silencers means treatment selection should be individualized rather than based on which therapy was historically available first.
Inotersen remains authorised in 2026 but EU supply is being discontinued
Tegsedi (inotersen) remains authorised for adult stage 1 or stage 2 hATTR polyneuropathy, but EMA reports that the company is permanently discontinuing supply and that it will be unavailable in the EU by the end of 2026 for commercial reasons. A patient already receiving inotersen should therefore ask the treating amyloidosis center about continuity and transition planning rather than assuming long-term German availability.
Vitamin A and drug-specific monitoring are part of treatment, not optional extras
TTR-silencing therapies reduce circulating transthyretin, which transports retinol-binding protein. EMA product information for current silencers includes vitamin A supplementation and other therapy-specific precautions. Monitoring also differs by drug: infusion reactions, renal/hepatic status, platelet risk for inotersen and other factors should be reviewed according to the selected medicine rather than applying one generic monitoring schedule to all agents.
Historic liver transplantation is no longer the only disease-modifying strategy
Because transthyretin is mainly produced in the liver, transplantation historically played a central role in selected hereditary ATTR cases. Modern stabilizers and gene-silencing therapies have changed that landscape. Transplantation is now a specialist multidisciplinary decision influenced by variant, age, disease stage and organ involvement rather than the default treatment for a patient with newly diagnosed ATTRv polyneuropathy.
What to send for a German hATTR second opinion
A useful review should document the molecular diagnosis, neurological stage and systemic phenotype before travel is planned.
- Complete TTR genetic report with exact variant and classification
- Family history and previous genetic-counseling documents
- Neurology reports, nerve-conduction/EMG results and functional stage
- Autonomic symptoms, gastrointestinal history and weight trajectory
- Cardiology records: ECG, echocardiography, biomarkers, cardiac MRI or scintigraphy if performed
- Biopsy and amyloid-typing report if tissue diagnosis was used
- Current or previous patisiran, vutrisiran, eplontersen, tafamidis or inotersen therapy
- Vitamin A supplementation and drug-specific monitoring results
- Kidney, liver and blood-count results relevant to treatment selection
- A specific question: confirm ATTRv, stage polyneuropathy, compare disease-modifying therapy, assess mixed cardiac disease or plan a treatment switch
Rapid cardiac or neurological deterioration needs local assessment first
Stable ATTRv can be reviewed internationally, but syncope with suspected arrhythmia, acute heart-failure decompensation, severe orthostatic collapse, rapidly progressive weakness with inability to walk safely or another acute deterioration should be assessed and stabilized locally before medical travel.
Official sources
Sources last checked 2026-09-02. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Amyloidosis outpatient clinic – familial TTR amyloid polyneuropathy — Heidelberg University Hospital ↗
- Transthyretin amyloidosis — Heidelberg University Hospital ↗
- Amyloidosis clinic – familial amyloid polyneuropathies / hATTR — Charité – Universitätsmedizin Berlin ↗
- Interdisciplinary Amyloidosis Center Northern Bavaria — University Hospital Würzburg ↗
- Wainzua EPAR — European Medicines Agency ↗
- Amvuttra EPAR — European Medicines Agency ↗
- Onpattro EPAR — European Medicines Agency ↗
- Vyndaqel EPAR — European Medicines Agency ↗
- Tegsedi EPAR and EU supply information — European Medicines Agency ↗